<DOC>
	<DOCNO>NCT00085462</DOCNO>
	<brief_summary>RATIONALE : Inserting gene create laboratory person 's white blood cell may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Vaccines may make body build immune response kill tumor cell . Combining gene-modified white blood cell infusion interleukin-2 vaccine therapy may kill tumor cell . PURPOSE : This phase I trial study well give gene-modified white blood cell give together interleukin-2 vaccine therapy work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Gene-Modified White Blood Cells Followed By Interleukin-2 Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine , preliminarily , clinical tumor regression lymphodepleted patient metastatic melanoma treat fowlpox gp100 antigen immunization antitumor antigen T-cell receptor ( TCR ) -engineered tumor infiltrate lymphocyte CD8+ autologous peripheral blood lymphocyte follow interleukin-2 . Secondary - Determine vivo survival TCR gene-engineered cell patient treat regimen . OUTLINE : Patients stratify accord ability produce tumor-infiltrating lymphocyte ( TIL ) ( yes v ) . Patients receive lymphodepleting chemotherapy comprise cyclophosphamide IV 1 hour day -7 -6 fludarabine IV 30 minute day -5 -1 . - Stratum 1 ( TIL ) : Patients receive TIL retrovirally transduce gp100 antigen TCR gene IV 20-30 minute day 0* . - Stratum 2 ( CD8+peripheral blood lymphocyte [ PBL ] ) : Patients receive CD8+PBL retrovirally transduce gp100 antigen TCR gene IV 20-30 minute day 0* . NOTE : *Day 0 1-4 day last dose fludarabine . Patients stratum also receive fowlpox-gp100 vaccine ( TIL/PBL infusion ) IV 1-2 minute day 0 28 high-dose interleukin-2 ( IL-2 ) IV 15 minute every 8 hour day 0-4 day 28-32 . Patients also receive G-CSF SC daily begin day 0 continue blood count recover . Treatment continue absence disease progression unacceptable toxicity . Beginning 6-8 week last dose vaccine high-dose IL-2 , patient stable respond disease may receive 1 retreatment course . Responding patient follow 1 , 3 , 6 , 12 month annually thereafter . PROJECTED ACCRUAL : A total 61 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma Metastatic disease Measurable disease Refractory standard therapy , include highdose interleukin2 therapy HLAA*0201 positive Progressive disease prior immunization melanoma antigens OR prior treatment anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody ( MDX010 ) cellular therapy without myeloablation allow provide toxicity resolve ≤ grade 2 ( except vitiligo ) AND patient require systemic steroid No brain metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL Lymphocyte count &gt; 500/mm^3 WBC &gt; 3,000/mm^3 No coagulation disorder Hepatic AST ALT &lt; 3 time upper limit normal ( ULN ) Bilirubin ≤ 2.0 mg/dL ( 3.0 mg/dL patient Gilbert 's syndrome ) Hepatitis B surface antigen negative Hepatitis C antibody negative ( unless antigen negative ) Renal Creatinine ≤ 1.6 mg/dL Cardiovascular LVEF ≥ 45 % cardiac stress test No LVEF &lt; 45 % patient ≥ 50 year age No myocardial infarction No cardiac arrhythmias No symptomatic cardiac ischemia No prior EKG abnormalities No major cardiovascular illness Pulmonary FEV_1 ≥ 60 % predict AND obstructive restrictive pulmonary disease No symptoms respiratory dysfunction No major respiratory illness Immunologic HIV negative EpsteinBarr virus positive No active systemic infection ( include opportunistic infection ) No form primary ( e.g. , autoimmune colitis Crohn 's disease ) secondary immunodeficiency ( due chemotherapy radiotherapy ) No prior severe immediate hypersensitivity reaction study agent include egg No major illness immune system Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study participation Willing complete durable power attorney ( DPA ) PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 6 week since prior MDX010 Chemotherapy Not specify Endocrine therapy See Disease Characteristics No concurrent systemic steroid therapy Radiotherapy Not specify Surgery Not specify Other More 4 week since prior systemic therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>